Manufacturer record
Orison Pharma International: regulatory record
Last checked 3 November 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
12 batches manufactured by Orison Pharma International (Himachal Pradesh) were declared Not of Standard Quality between February 2019 and July 2026. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Most recent flagged batch: 25D-BT150, Cefixime Dispersible Tablets IP 200mg (exp Jun 2027). FDAL, Chhatrapati Sambhajinagar (state lab) found it not of standard quality: The Sample does not Comply for Description as the Tablets shows Light Brown coloured Spots all over the Surface of the Tablets. Listed in the July 2026 alert.
Records by type
12 records linked to Orison Pharma International in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Cefixime Dispersible Tablets IP 200mg | Batch 25D-BT150Mfg Jul 2025 · Exp Jun 2027 | The Sample does not Comply for Description as the Tablets shows Light Brown coloured Spots all over the Surface of the Tablets.Description | FDAL, Chhatrapati SambhajinagarState lab | Jul 2026 |
| Pantoprazole Tablets IP 40 mg | Batch 25A-T126BMfg Apr 2025 · Exp Mar 2027 | The sample does not conform to I.P 2022 requirements w.r.t the test for," Dissolution"Dissolution | DTL,DALGATE SRINAGAR KASHMIR( J AND K)State lab | Nov 2025 |
| Pantoprazole Tablets IP 20 mg (Opipan- 20) | Batch 23G-T1503Mfg Oct 2023 · Exp Sep 2025 | Dissolution in Acid Stage & DescriptionDissolution | RDTL GuwahatiCDSCO lab | Jun 2025 |
| Telmisartan Tablets IP (TELMOPI-40 Tablets) | Batch 23I-T2013Mfg Dec 2023 · Exp Nov 2025 | DissolutionDissolution | RDTL GuwahatiCDSCO lab | Feb 2025 |
| Telmisartan Tablets I.P.. (TELMOPI-40) | Batch 23I-T2003Mfg Dec 2023 · Exp Nov 2025 | DissolutionDissolution | RDTL GuwahatiCDSCO lab | Dec 2024 |
| Pantoprazole Tablets IP (Opipan-40) | Batch 23D-T812AMfg Jul 2023 · Exp Jun 2025 | DescriptionDescription | RDTL GuwahatiCDSCO lab | Nov 2024 |
| Itraconazole Capsules BP 200 mg (Itropi- 200) | Batch 23K-C354Mfg Feb 2024 · Exp Jan 2026 | DissolutionDissolution | RDTL GuwahatiCDSCO lab | Nov 2024 |
| Enalapril Maleate Tablets IP 5 mg (Opioril- 5) | Batch 23HT1771Mfg Nov 2023 · Exp Oct 2025 | Dissolution and Assay of Enalapril MaleateAssay | CDTL MumbaiCDSCO lab | Oct 2024 |
| Albendazole Tablets IP (Opida- 400) | Batch 23A-T149Mfg Apr 2023 · Exp Mar 2025 | DissolutionDissolution | RDTL GuwahatiState lab | Dec 2023 |
| Cefixime Dispersible Tablets IP (Cefimax-100 DT) | Batch 20D-BT016Mfg Jul 2020 · Exp Jun 2022 | Uniformity Of DispersionUniformity of weight/content | RDTL GuwahatiCDSCO lab | Jul 2021 |
| AMOXYCILLIN & CLOXACILLIN CAPSULES (OPIMOX-CL) | Batch 18A-BC001Mfg Apr 2018 · Exp Mar 2020 | Assay of Amoxycillin& Assay of CloxacillinAssay | RDTL GuwahatiState lab | Mar 2019 |
| Cefpodoxime Oral Suspension I.P. (MONOPOD) | Batch 17J-BD502Mfg Jan 2018 · Exp Jun 2019 | AssayAssay | Drugs Control Department, Arunachal PradeshCDSCO lab | Feb 2019 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.